Arcutis Biotherapeutics Reconciled Depreciation Over Time
| ARQT Stock | USD 12.69 0.44 3.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arcutis Biotherapeutics Performance and Arcutis Biotherapeutics Correlation. Arcutis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcutis Biotherapeutics. If investors know Arcutis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcutis Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 1.228 | Quarterly Revenue Growth 0.174 | Return On Assets (0.31) | Return On Equity (1.92) |
The market value of Arcutis Biotherapeutics is measured differently than its book value, which is the value of Arcutis that is recorded on the company's balance sheet. Investors also form their own opinion of Arcutis Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcutis Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcutis Biotherapeutics' market value can be influenced by many factors that don't directly affect Arcutis Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcutis Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcutis Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcutis Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Reconciled Depreciation Analysis
Compare Arcutis Biotherapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Reconciled Depreciation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 195 K | 394 K | 512 K | 1 M | 881 K | 564.5 K |
| ABOS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4 K | 169 K | 194 K | 100.9 K |
| INZY | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 83 K | 217 K | 674 K | 744 K | 822 K | 470.4 K |
| XFOR | 195 K | 195 K | 195 K | 195 K | 195 K | 195 K | 195 K | 195 K | 155 K | 103 K | 351 K | 499 K | 513 K | 481 K | 361 K |
| MIRM | 324 K | 324 K | 324 K | 324 K | 324 K | 324 K | 324 K | 324 K | 324 K | 324 K | 623 K | 975 K | 3.7 M | 7 M | 7.3 M |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 155 K | 199 K | 531 K | 383 K | 279 K |
| APLS | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 11.9 K | 239.7 K | 239.7 K | 637 K | 1.5 M | 1.5 M | 1.7 M | 1 M |
| SPRO | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 409 K | 750 K | 761 K | 646 K | 869 K | 367 K | 654.5 K |
| BOLT | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 302 K | 335 K | 611 K | 1.2 M | 1.7 M | 1.8 M | 1.1 M |
| CHRS | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.2 M | 3.3 M | 2.9 M | 3.5 M | 3.7 M | 3.8 M | 3.7 M |
| GLUE | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 537 K | 2.1 M | 3.7 M | 5.4 M | 5.7 M |
| DSGN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5 K | 129 K | 406 K | 523 K | 549.1 K |
| ERAS | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 540 K | 829 K | 2.6 M | 3.7 M | 3.9 M |
Arcutis Biotherapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Reconciled Depreciation description
My Equities
My Current Equities and Potential Positions
| Arcutis Biotherapeutics | ARQT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 12.69
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.